AI Engines For more Details: Perplexity Kagi Labs You
Allergic Reactions: Some individuals may experience allergic reactions or hypersensitivity to polysorbate 80. Symptoms of an allergic reaction may include skin rash, itching, hives, swelling, difficulty breathing, or anaphylaxis. Individuals with known allergies to polysorbate 80 or related compounds should avoid products containing this ingredient and seek medical attention if they experience any adverse reactions.
Gastrointestinal Disturbances: Ingestion of large amounts of polysorbate 80 may lead to gastrointestinal disturbances such as nausea, vomiting, diarrhea, or abdominal discomfort in sensitive individuals. These symptoms are more likely to occur with high doses or prolonged exposure to polysorbate 80-containing products.
Impact on Gut Microbiota: Some research suggests that polysorbate 80 may have an impact on the gut microbiota, the community of microorganisms living in the digestive tract. Studies in animals have shown that polysorbate 80 consumption can alter the composition and diversity of gut bacteria, potentially disrupting the balance between beneficial and harmful microbes. However, the significance of these findings in humans and their implications for health remain unclear.
Potential Effects on Reproductive Health: There is limited research suggesting that polysorbate 80 may have adverse effects on reproductive health. Animal studies have shown that high doses of polysorbate 80 may disrupt hormonal balance and reproductive function in male rats, leading to reduced sperm quality and fertility. However, more research is needed to determine the relevance of these findings to humans and the potential risks associated with polysorbate 80 exposure.
Impact on Blood-Brain Barrier: Some studies have suggested that polysorbate 80 may have the ability to transiently disrupt the blood-brain barrier (BBB), the protective barrier that separates the bloodstream from the brain. This property of polysorbate 80 has been utilized in research to enhance the delivery of therapeutic agents to the brain in certain neurological conditions. However, prolonged or excessive disruption of the BBB may have implications for neurological health and function.
Rank | Probiotic | Impact |
---|---|---|
order | Rhodospirillales | Increases |
species | Akkermansia muciniphila | Increases |
species group | Pseudomonas putida group | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
---|---|---|---|
Abdominal Aortic Aneurysm | 0.2 | 0.2 | |
Acne | 0.6 | 0.6 | 0 |
ADHD | 2.2 | 1.3 | 0.69 |
Age-Related Macular Degeneration and Glaucoma | 0.6 | 0.4 | 0.5 |
Allergic Rhinitis (Hay Fever) | 1.4 | 0.9 | 0.56 |
Allergies | 1.3 | 1.3 | 0 |
Allergy to milk products | 1.4 | 1.1 | 0.27 |
Alopecia (Hair Loss) | 0.4 | 2 | -4 |
Alzheimer's disease | 3.3 | 3.3 | 0 |
Amyotrophic lateral sclerosis (ALS) Motor Neuron | 1.7 | 2.6 | -0.53 |
Ankylosing spondylitis | 2.7 | 2.5 | 0.08 |
Anorexia Nervosa | 2.3 | 0.2 | 10.5 |
Asthma | 2 | 1.4 | 0.43 |
Atherosclerosis | 1 | 0.2 | 4 |
Atrial fibrillation | 1 | 2.8 | -1.8 |
Autism | 5.8 | 6.1 | -0.05 |
Barrett esophagus cancer | 0.6 | -0.6 | |
benign prostatic hyperplasia | 0.2 | 0.2 | |
Bipolar Disorder | 0.9 | 0.7 | 0.29 |
Brain Trauma | 0.2 | 1.2 | -5 |
Breast Cancer | 0.2 | -0.2 | |
Carcinoma | 1.6 | 1.3 | 0.23 |
Celiac Disease | 2 | 1.9 | 0.05 |
Cerebral Palsy | 1 | 0.9 | 0.11 |
Chronic Fatigue Syndrome | 3.4 | 1.7 | 1 |
Chronic Kidney Disease | 1.7 | 1.4 | 0.21 |
Chronic Lyme | 0.2 | 0.2 | 0 |
Chronic Obstructive Pulmonary Disease (COPD) | 1 | 0.8 | 0.25 |
Chronic Urticaria (Hives) | 0.6 | 1.2 | -1 |
Coagulation / Micro clot triggering bacteria | 2.3 | 2.3 | |
Colorectal Cancer | 2.2 | 1.3 | 0.69 |
Constipation | 1.6 | 2.5 | -0.56 |
Coronary artery disease | 2.1 | 1.4 | 0.5 |
COVID-19 | 5.8 | 5.1 | 0.14 |
Crohn's Disease | 4.4 | 5 | -0.14 |
cystic fibrosis | 1.4 | 0.2 | 6 |
deep vein thrombosis | 1.3 | 1.3 | |
Depression | 6 | 6.2 | -0.03 |
Dermatomyositis | 1 | -1 | |
Eczema | 0.8 | 0.6 | 0.33 |
Endometriosis | 1.1 | 1.6 | -0.45 |
Eosinophilic Esophagitis | 0.8 | -0.8 | |
Epilepsy | 3.2 | 2.9 | 0.1 |
erectile dysfunction | 0.8 | -0.8 | |
Fibromyalgia | 1 | 1.6 | -0.6 |
Functional constipation / chronic idiopathic constipation | 2.4 | 3.1 | -0.29 |
gallstone disease (gsd) | 0.4 | 1.6 | -3 |
Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.6 | 0.8 | -0.33 |
Generalized anxiety disorder | 0.2 | 2.5 | -11.5 |
giant cell arteritis | 0.5 | 0.5 | |
Glioblastoma | 0.8 | 0.2 | 3 |
Gout | 2 | 2 | |
Graves' disease | 2.9 | 0.5 | 4.8 |
Halitosis | 0.9 | 0.9 | |
Hashimoto's thyroiditis | 0.5 | 3 | -5 |
Hemorrhoidal disease, Hemorrhoids, Piles | 0 | 0 | |
Hidradenitis Suppurativa | 0.5 | 0.5 | |
Histamine Issues,Mast Cell Issue, DAO Insufficiency | 1.9 | 1.2 | 0.58 |
hypercholesterolemia (High Cholesterol) | 0.6 | 0.2 | 2 |
hyperglycemia | 2 | 0.9 | 1.22 |
Hyperlipidemia (High Blood Fats) | 0.4 | 2.9 | -6.25 |
hypersomnia | 0.4 | 0.2 | 1 |
hypertension (High Blood Pressure | 3.3 | 1.1 | 2 |
Hypothyroidism | 1.8 | 1.8 | |
Hypoxia | 0.2 | 0.8 | -3 |
IgA nephropathy (IgAN) | 0.6 | 0.9 | -0.5 |
Inflammatory Bowel Disease | 3.3 | 2.1 | 0.57 |
Insomnia | 1.5 | 1.3 | 0.15 |
Intelligence | 0.5 | 1.8 | -2.6 |
Intracranial aneurysms | 0.2 | 0.4 | -1 |
Irritable Bowel Syndrome | 2.9 | 2.7 | 0.07 |
Liver Cirrhosis | 2 | 2.9 | -0.45 |
Long COVID | 4.2 | 7.9 | -0.88 |
Low bone mineral density | 1.2 | 0.6 | 1 |
Lung Cancer | 1.6 | 0.3 | 4.33 |
ME/CFS with IBS | 0.4 | 0.2 | 1 |
ME/CFS without IBS | 0.8 | 1 | -0.25 |
Metabolic Syndrome | 5.7 | 4.6 | 0.24 |
Mood Disorders | 6.7 | 7.9 | -0.18 |
multiple chemical sensitivity [MCS] | 0.4 | 0.6 | -0.5 |
Multiple Sclerosis | 1.7 | 3.3 | -0.94 |
Multiple system atrophy (MSA) | 0.4 | 1 | -1.5 |
myasthenia gravis | 0.2 | -0.2 | |
Neuropathy (all types) | 0.6 | 1.6 | -1.67 |
neuropsychiatric disorders (PANDAS, PANS) | 1.3 | 1.3 | |
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 2.5 | 2.9 | -0.16 |
Obesity | 4.9 | 4.8 | 0.02 |
obsessive-compulsive disorder | 3.6 | 1.5 | 1.4 |
Osteoarthritis | 0.2 | 1.2 | -5 |
Osteoporosis | 1.5 | 0.8 | 0.88 |
Parkinson's Disease | 4 | 2.9 | 0.38 |
Polycystic ovary syndrome | 2 | 2.5 | -0.25 |
Postural orthostatic tachycardia syndrome | 0.2 | 0.2 | 0 |
Premenstrual dysphoric disorder | 0.2 | 0.6 | -2 |
primary biliary cholangitis | 0.4 | 0.8 | -1 |
Psoriasis | 1.2 | 1.7 | -0.42 |
rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 4 | 5.7 | -0.43 |
Rosacea | 0.8 | 0.4 | 1 |
Schizophrenia | 3 | 3.3 | -0.1 |
scoliosis | 1 | -1 | |
sensorineural hearing loss | 0.9 | 0.9 | |
Sjögren syndrome | 2.3 | 1.1 | 1.09 |
Sleep Apnea | 1 | 1.7 | -0.7 |
Small Intestinal Bacterial Overgrowth (SIBO) | 0.5 | 0.5 | |
Stress / posttraumatic stress disorder | 1.7 | 1.8 | -0.06 |
Systemic Lupus Erythematosus | 3.5 | 3.6 | -0.03 |
Tic Disorder | 0.4 | 0.5 | -0.25 |
Tourette syndrome | 0.2 | 0.8 | -3 |
Type 1 Diabetes | 2.1 | 2.2 | -0.05 |
Type 2 Diabetes | 4.4 | 4.4 | 0 |
Ulcerative colitis | 3.1 | 4.2 | -0.35 |
Unhealthy Ageing | 1.4 | 1.2 | 0.17 |
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Explanations/Info/Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations. Please report any to us for correction.
Copyright 2016-2024 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 Β§β―1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.